<DOC>
	<DOCNO>NCT01777152</DOCNO>
	<brief_summary>This double-blind , randomize , multicenter , phase 3 clinical trial compare efficacy safety brentuximab vedotin combination CHP standard-of-care CHOP patient CD30-positive mature T-cell lymphoma .</brief_summary>
	<brief_title>ECHELON-2 : A Comparison Brentuximab Vedotin CHP With Standard-of-care CHOP Treatment Patients With CD30-positive Mature T-cell Lymphomas</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Lymphoma , Large-Cell , Anaplastic</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Peripheral</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Patients newly diagnose , CD30positive mature Tcell lymphomas Fluorodeoxyglucose ( FDG ) avid disease PET measurable disease least 1.5 cm CT Eastern Cooperative Oncology Group ( ECOG ) performance status less equal 2 History another primary invasive malignancy remission least 3 year Current diagnosis primary cutaneous CD30positive Tcell lymphoproliferative disorder lymphomas mycosis fungoides History progressive multifocal leukoencephalopathy ( PML ) Cerebral/meningeal disease relate underlying malignancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Antibodies , Monoclonal</keyword>
	<keyword>Antibody-Drug Conjugate</keyword>
	<keyword>Antigens , CD30</keyword>
	<keyword>Drug Therapy</keyword>
	<keyword>Hematologic Diseases</keyword>
	<keyword>Lymphoma</keyword>
	<keyword>Monomethyl auristatin E</keyword>
	<keyword>Lymphoma , T-Cell</keyword>
	<keyword>Lymphoma , Non-Hodgkin</keyword>
	<keyword>Lymphoma , Large-Cell , Anaplastic</keyword>
</DOC>